



**Neurosurgery**

Thomas M. Wascher, MD, FACS  
 Karl A. Greene, MD, PhD  
 David R. Bond, APNP, CNRN  
 Jill E. Coenen, RN

**Orthopedic Spine Surgery**

Peter F. Ullrich, Jr., MD  
 David C. DeWitt, MD  
 Pamela E. Verkuilen, APNP

**Physical Medicine and Rehabilitation**

John P. Revord, MD, FAAPMR  
 Richard A. Staehler, MD, FAAPMR  
 J. Talbot Sellers, DO, FAAPMR  
 Randall J. Schultz, MD, FAAPMR  
 Douglas J. Hendricks, MD, FAAPMR

**GLIOMA OUTCOMES DATA (2006)**

Grade II Glioma

**Literature Summary**

182 weeks

**NeuroSpine (Dr. Wascher)**

377+ weeks

Grade III (Anaplastic) Astrocytoma

**Literature Summary**

Average survival:  
 One year survival:  
 Two year survival:  
 Five year survival:

83.2 weeks  
 75%  
 46  
 19%

**NeuroSpine (Dr. Wascher)**

313.2+ weeks  
 100%  
 89%  
 52%+

Grade IV (Glioblastoma Multiforme)

**Literature Summary**

Average survival:  
 One year survival:  
 Two year survival:  
 Three year survival:

34 weeks  
 42%  
 18%  
 12%

**NeuroSpine (Dr. Wascher)**

72.4+ weeks  
 52%  
 22%  
 12%+

Malignant Glioma (Grade III & IV)

**Literature Summary**

Median survival:  
 One year survival:  
 Two year survival:  
 Long term (>5 year) survival:

14 months  
 60%  
 25%  
 6%

**NeuroSpine (Dr. Wascher)**

21 months  
 64%  
 43%+  
 21%+